Immatics (NasdaqCM:IMTX) Valuation Check After Dilutive Follow-On Equity Offering and Sharp One-Day Share Price Drop

Simply Wall St.12-08

Immatics (NasdaqCM:IMTX) just priced a follow on equity offering, selling 12,500,000 new shares at 10 dollars each to raise about 125 million dollars, a move that directly affects shareholder dilution...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2589354549?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","is_english":true,"pubTime":"2025-12-08 22:18","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2589354549","market":"nz","top_or_hot":-1,"title":"Immatics (NasdaqCM:IMTX) Valuation Check After Dilutive Follow-On Equity Offering and Sharp One-Day Share Price Drop","media":"Simply Wall St.","content":"<div>\n<p>Immatics (NasdaqCM:IMTX) just priced a follow on equity offering, selling 12,500,000 new shares at 10 dollars each to raise about 125 million dollars, a move that directly affects shareholder dilution...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-imtx/immatics/news/immatics-nasdaqcmimtx-valuation-check-after-dilutive-follow\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Immatics (NasdaqCM:IMTX) Valuation Check After Dilutive Follow-On Equity Offering and Sharp One-Day Share Price Drop</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nImmatics (NasdaqCM:IMTX) Valuation Check After Dilutive Follow-On Equity Offering and Sharp One-Day Share Price Drop\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-12-08 22:18 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-imtx/immatics/news/immatics-nasdaqcmimtx-valuation-check-after-dilutive-follow><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Immatics (NasdaqCM:IMTX) just priced a follow on equity offering, selling 12,500,000 new shares at 10 dollars each to raise about 125 million dollars, a move that directly affects shareholder dilution...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-imtx/immatics/news/immatics-nasdaqcmimtx-valuation-check-after-dilutive-follow\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4585","symbol_name":"ETF&股票定投概念","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-imtx/immatics/news/immatics-nasdaqcmimtx-valuation-check-after-dilutive-follow","article_id":"2589354549","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-imtx/immatics/news/immatics-nasdaqcmimtx-valuation-check-after-dilutive-follow","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2589354549","pubTimestamp":1765203518,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Immatics (NasdaqCM:IMTX) just priced a follow on equity offering, selling 12,500,000 new shares at 10 dollars each to raise about 125 million dollars, a move that directly affects shareholder dilution and funding runway.\nSee our latest analysis for Immatics.\nThe sharp 1 day share price return of negative 14.24 percent after the raise comes on the back of a powerful 90 day share price return of 75.82 percent and 1 year total shareholder return of 30.85 percent, suggesting momentum is cooling...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4585":"ETF&股票定投概念","EQR":"资产住宅公司","IMTX":"Immatics N.V.","BK4139":"生物科技","BK4215":"住宅房地产投资信托","BK4588":"碎股"},"translate_title":"Immatics（纳斯达克CM：IMTX）在稀释性后续股票发行和单日股价大幅下跌后进行估值检查","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"EQR":1.5,"IMTX":1.5},"content_text":"Immatics (NasdaqCM:IMTX) just priced a follow on equity offering, selling 12,500,000 new shares at 10 dollars each to raise about 125 million dollars, a move that directly affects shareholder dilution and funding runway. See our latest analysis for Immatics. The sharp 1 day share price return of negative 14.24 percent after the raise comes on the back of a powerful 90 day share price return of 75.82 percent and 1 year total shareholder return of 30.85 percent, suggesting momentum is cooling but the broader rerating remains intact. If you are weighing biotech risk reward trade offs after Immatics latest move, it is worth exploring other healthcare stocks that might have a different balance of growth and dilution risk. With shares still trading at a steep discount to analyst targets despite robust revenue growth but persistent losses, investors now face a pivotal question: Is Immatics undervalued after the raise, or already pricing in its future growth? AdvertisementPrice-to-Sales of 12.5x: Is it justified? Immatics last closed at 10.18 dollars and the stock screens as expensive on a price-to-sales basis compared with both peers and the wider biotech group. The preferred multiple here is the price-to-sales ratio, which compares the companys market value with its annual revenue. This is a common yardstick for loss making, high growth biotechs where earnings are not yet meaningful. Immatics trades on a price-to-sales ratio of 12.5 times, above both its direct peer average of 10.3 times and the broader US biotech industry at 12 times. This implies investors are already paying a premium for its pipeline and forecast growth, even though our fair price-to-sales indicator suggests a much lower level of about 1 times as a potential anchor the market could converge toward if sentiment cools. That premium multiple stands out, not just versus comparable biotech names but also against the estimated fair ratio. It signals a valuation that is materially richer than what fundamentals alone might justify if execution or trial news were to disappoint. Explore the SWS fair ratio for Immatics Result: Price-to-Sales of 12.5x (OVERVALUED) However, setbacks in pivotal trials or slower than expected revenue traction from its TCR pipeline could quickly compress that premium valuation. Find out about the key risks to this Immatics narrative.  Build Your Own Immatics Narrative If you see the story differently, or prefer digging into the numbers yourself, you can quickly build a personalized view in under three minutes: Do it your way. A great starting point for your Immatics research is our analysis highlighting 1 key reward and 2 important warning signs that could impact your investment decision. Ready for your next opportunity? Immatics might be compelling, but your next big win could be hiding elsewhere; use the Simply Wall St Screener now so you do not miss it.  Capture potential mispricings by targeting these 902 undervalued stocks based on cash flows that the market has not fully appreciated yet. Capitalize on powerful technological shifts by zeroing in on these 26 AI penny stocks positioned at the forefront of innovation. Strengthen your income strategy by focusing on these 15 dividend stocks with yields > 3% that can help anchor long term returns.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.New: AI Stock Screener & AlertsOur new AI Stock Screener scans the market every day to uncover opportunities.• Dividend Powerhouses (3%+ Yield)• Undervalued Small Caps with Insider Buying• High growth Tech and AI CompaniesOr build your own from over 50 metrics.Explore Now for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"shareholding","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2589354549","isCrawlerRequest":true}